Lataa...
Abrogating endocrine resistance by targeting ERα and PI3K in breast cancer
Antiestrogen therapies targeting estrogen receptor α (ER) signaling are a mainstay for patients with ER+ breast cancer. While many cancers exhibit resistance to antiestrogen therapies, a large body of clinical and experimental evidence indicates that hyperactivation of the phosphatidylinositol 3-kin...
Tallennettuna:
| Päätekijät: | , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Frontiers Media S.A.
2012
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3472546/ https://ncbi.nlm.nih.gov/pubmed/23087906 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2012.00145 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|